Patents Assigned to IRM LLC
  • COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS
    Publication number: 20110177055
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g.
    Type: Application
    Filed: March 29, 2011
    Publication date: July 21, 2011
    Applicant: IRM LLC
    Inventors: David C. Tully, Arnab K. Chatterjee, Hank Michael James Petrassi, Badry Bursulaya, Glen Spraggon
  • COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS
    Publication number: 20110172278
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by G protein-coupled receptors, in particular G protein-coupled receptor 120.
    Type: Application
    Filed: June 23, 2009
    Publication date: July 14, 2011
    Applicant: IRM LLC
    Inventors: Xiaohui He, Xuefeng Zhu, Kunyong Yang, Robert Epple, Hong Liu
  • COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
    Publication number: 20110172244
    Abstract: The invention provides compounds, of Formula I: pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: February 20, 2009
    Publication date: July 14, 2011
    Applicant: IRM LLC
    Inventors: Phillip B. Alper, Robert Epple, Pierre-Yves Michellys, Daniel Mutnick, Victor Nikulin
  • COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
    Publication number: 20110166176
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: February 20, 2009
    Publication date: July 7, 2011
    Applicant: IRM LLC
    Inventors: Phillip B. Alper, Christopher Cow, Robert Epple, Pierre-Yves Michellya, Daniel Mutnick
  • FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS
    Publication number: 20110166133
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly Ros, KDR, FMS, C-FMS, FLT3, c-Kit, JAK2, JAK3, Aurora, PDGFR, Lck, TrkA, TrkB, TrkC, IGF-IR, ALK4, ALK5 and ALK or combinations thereof.
    Type: Application
    Filed: May 7, 2009
    Publication date: July 7, 2011
    Applicant: IRM LLC
    Inventors: Pamela A. Albaugh, Ha-Soon Choi, Gregory Chopiuk, Yi Fan, Paul Vincent Rucker, Zhicheng Wang
  • ANTAGONISTS OF PROTEASE ACTIVATED RECEPTOR-1 (PAR1)
    Publication number: 20110158999
    Abstract: The present invention provides antibodies or antigen-binding molecules that specifically recognize and antagonize human PAR1 receptor. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.
    Type: Application
    Filed: January 7, 2011
    Publication date: June 30, 2011
    Applicant: IRM LLC
    Inventors: Steve B. Cohen, Marc Nasoff
  • HEDGEHOG PATHWAY MODULATORS
    Publication number: 20110152282
    Abstract: The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).
    Type: Application
    Filed: August 24, 2009
    Publication date: June 23, 2011
    Applicant: IRM LLC
    Inventors: Dai Cheng, Dong Han, Guobao Zhang, Yongqin Wan, Yun Feng Xie, Jiqing Jiang, Wenqi Gao, Shifeng Pan
  • COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA
    Publication number: 20110144107
    Abstract: The invention provides a class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    Type: Application
    Filed: June 11, 2009
    Publication date: June 16, 2011
    Applicants: IRM LLC, DANA-FARBER CANCER INSTITUTE INC.
    Inventors: Arnab K. Chatterjee, Advait Nagle, Tao Wu, Nathanael S. Gray
  • PCSK9 ANTAGONISTS
    Publication number: 20110142849
    Abstract: The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.
    Type: Application
    Filed: December 10, 2010
    Publication date: June 16, 2011
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: SARAH RUE, STEVE B. COHEN, JUN LI, DAVID YOWE
  • Compounds and compositions as channel activating protease inhibitors
    Patent number: 7951823
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.
    Type: Grant
    Filed: May 16, 2007
    Date of Patent: May 31, 2011
    Assignee: IRM LLC
    Inventors: David C. Tully, Arnab K. Chatterjee, Agnes Vidal, Hank Michael James Petrassi, Zhiwei Wang, Badry Bursulaya, Glen Spraggon
  • Compounds and compositions as channel activating protease inhibitors
    Patent number: 7939547
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: May 10, 2011
    Assignee: IRM LLC
    Inventors: David C. Tully, Arnab K. Chatterjee, Hank Michael James Petrassi, Badry Bursulaya, Glen Spraggon
  • 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS
    Publication number: 20110098280
    Abstract: Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: January 4, 2011
    Publication date: April 28, 2011
    Applicants: Novartis AG, IRM LLC
    Inventors: Carlos Garcia-Echeverria, Takanori Kanazawa, Eiji Kawahara, Keiichi Masuya, Naoko Matsuura, Takahiro Miyake, Osamu Ohmori, Ichiro Umemura, Ruo Steensma, Greg Chopiuk, Jiqing Jiang, Yongqin Wan, Qiang Ding, Qiong Zhang, Nathanael Schiander Gray, Donald Karanewsky
  • ANTI-TRKB ANTIBODIES
    Publication number: 20110097326
    Abstract: The present invention provides improved antibodies or antigen-binding molecules that specifically recognize and agonize the tyrosine receptor kinase B (TrkB) receptor, and methods of their use. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.
    Type: Application
    Filed: January 16, 2009
    Publication date: April 28, 2011
    Applicant: IRM LLC
    Inventor: Kenneth R. Luehrsen
  • Compounds and compositions as hedgehog signaling pathway modulators
    Patent number: 7928133
    Abstract: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: April 19, 2011
    Assignee: IRM LLC
    Inventors: Dai Cheng, Dong Han, Wenqi Gao, Jiqing Jiang, Shifeng Pan, Yongqin Wan, Qihui Jin
  • COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
    Publication number: 20110081365
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is —CR4?CR5.
    Type: Application
    Filed: February 27, 2009
    Publication date: April 7, 2011
    Applicants: IRM LLC, Novartis 35
    Inventors: Alex Cortez, Yongkai Li, Pranab Mishra, Manmohan Singh, David Skibinski, Nicholas Valiante, Tom Yao-Hsiang Wu, Xiaoyue Zhang, Yefen Zou
  • COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES
    Publication number: 20110059934
    Abstract: The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.
    Type: Application
    Filed: July 9, 2010
    Publication date: March 10, 2011
    Applicant: IRM LLC
    Inventors: Arnab K. Chatterjee, Advait S. Nagle, Tao Wu, David C. Tully, Kelli L. Kuhen
  • 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20110053952
    Abstract: The invention provides compounds of Formula (I) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, Fms, KDR, c-raf or b-raf kinases.
    Type: Application
    Filed: August 18, 2008
    Publication date: March 3, 2011
    Applicant: IRM LLC
    Inventors: Donatella Chianelli, Valentina Molteni, Xiaolin Li, Xiaodong Liu, Juliet Nabakka, Jon Loren
  • COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS
    Publication number: 20110053893
    Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
    Type: Application
    Filed: September 1, 2010
    Publication date: March 3, 2011
    Applicants: IRM LLC, Novartis AG
    Inventors: Tom Yao Hsiang Wu, Yongkai Li, Alex Cortez, Kathy Yue, Xiaoyue Zhang, Manmohan Singh, David Skibinski
  • COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS
    Publication number: 20110053897
    Abstract: Provided herein area novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.
    Type: Application
    Filed: July 26, 2010
    Publication date: March 3, 2011
    Applicant: IRM LLC
    Inventors: Jianwei CHE, Bei Chen, Qiang Ding, Xueshi Hao, Xiaohui He, Songchun Jiang, Qihui Jin, Yunho Jin, Hong Liu, Yahua Liu, Barun Okram, Tetsuo Uno, Xu Wu, Kunyong Yang, Xuefeng Zhu
  • METHODS AND COMPOSITIONS FOR TREATING LYMPHOMA AND MYELOMA
    Publication number: 20110044991
    Abstract: This invention relates to the use of antagonists of the hedgehog signaling pathway to induce apoptosis of lymphoma and myeloma cells and to treat subjects suffering from various forms of lymphoma or myeloma.
    Type: Application
    Filed: September 27, 2006
    Publication date: February 24, 2011
    Applicant: IRM LLC
    Inventors: Christine Dierks, Markus Warmuth